Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Gyre Therapeutics (GYRE) EPS (Basic) (2016 - 2025)

Gyre Therapeutics (GYRE) has disclosed EPS (Basic) for 16 consecutive years, with $0.04 as the latest value for Q3 2025.

  • On a quarterly basis, EPS (Basic) rose 300.0% to $0.04 in Q3 2025 year-over-year; TTM through Sep 2025 was $0.08, a 105.76% increase, with the full-year FY2024 number at $0.14, up 109.93% from a year prior.
  • EPS (Basic) was $0.04 for Q3 2025 at Gyre Therapeutics, up from $0.01 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of $1.64 in Q2 2022 to a low of -$1.53 in Q4 2023.
  • A 5-year average of -$0.24 and a median of $0.01 in 2025 define the central range for EPS (Basic).
  • Peak YoY movement for EPS (Basic): tumbled 182.14% in 2021, then soared 356.25% in 2022.
  • Gyre Therapeutics' EPS (Basic) stood at -$0.64 in 2021, then plummeted by 100.0% to -$1.28 in 2022, then decreased by 19.53% to -$1.53 in 2023, then skyrocketed by 100.65% to $0.01 in 2024, then skyrocketed by 300.0% to $0.04 in 2025.
  • Per Business Quant, the three most recent readings for GYRE's EPS (Basic) are $0.04 (Q3 2025), $0.01 (Q2 2025), and $0.03 (Q1 2025).